A61K31/125

INHIBITION OF UNDESIRED SENSORY EFFECTS BY THE COMPOUND CAMPHOR

A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.

INHIBITION OF UNDESIRED SENSORY EFFECTS BY THE COMPOUND CAMPHOR

A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.

Oral antiseptic composition useful for treating oral mucositis
09801916 · 2017-10-31 ·

Antiseptic pharmaceutical composition useful for the treatment of painful lesions in oral mucosa, ulcerative and inflammatory lesions of different origin and the treatment and/or prevention of oral mucositis and stomatitis.

Oral antiseptic composition useful for treating oral mucositis
09801916 · 2017-10-31 ·

Antiseptic pharmaceutical composition useful for the treatment of painful lesions in oral mucosa, ulcerative and inflammatory lesions of different origin and the treatment and/or prevention of oral mucositis and stomatitis.

Oral antiseptic composition useful for treating oral mucositis
09801916 · 2017-10-31 ·

Antiseptic pharmaceutical composition useful for the treatment of painful lesions in oral mucosa, ulcerative and inflammatory lesions of different origin and the treatment and/or prevention of oral mucositis and stomatitis.

ORAL FORMULATIONS OF DEFERASIROX
20170290811 · 2017-10-12 ·

Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

ORAL FORMULATIONS OF DEFERASIROX
20170290811 · 2017-10-12 ·

Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

CAPSULE-CONTAINING POUCHED PRODUCT FOR ORAL USE
20220030928 · 2022-02-03 ·

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical.

CAPSULE-CONTAINING POUCHED PRODUCT FOR ORAL USE
20220030928 · 2022-02-03 ·

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical.

Pharmaceutical removal of neuronal extensions from a degenerating disc

The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.